Paracetamol (acetaminophen)

**Indication**
- Pain

**INN**
- Paracetamol

**Medicine type**
- Chemical agent

**List type**
- Core (EML)
  - (EMLc)

**Additional notes**
- *Not recommended for anti-inflammatory use due to lack of proven benefit to that effect.
- **The presence of both 120 mg/5 mL and 125 mg/5 mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided.

**Formulations**
- Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL (EMLc)
- Local > Rectal > Suppository: 100 mg; 250 mg (EMLc)
- Oral > Solid > dispersible tablet: 100 mg (EMLc); 250 mg (EMLc)
- Oral > Solid > tablet: 250 mg; 325 mg; 500 mg

**EML status history**
- First added in 1977 (TRS 615)
- Changed in 1979 (TRS 641)
- Changed in 1987 (TRS 770)
- Changed in 2007 (TRS 950)
- Changed in 2017 (TRS 1006)
- Changed in 2023 (TRS 1049)

**Sex**
- All

**Age**
- Also recommended for children

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Wikipedia**
- Paracetamol (acetaminophen)

**DrugBank**
- Paracetamol (Acetaminophen)

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the deletion of the 100 mg tablet formulation from the EML and EMLc
- strengths of paracetamol tablets should specified rather than given in a range
- the addition of a 250 mg strength suppository formulation to the EMLc
- the addition of paracetamol dispersible tablets (100 mg and 250 mg) to the EMLc
- the addition of 250 mg/5mL strength oral liquid formulation to the EMLc
- the addition of a note stating "the presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided"